Thus, we analyzed the distribution of CD4+ and CD8+ T cells in tumor tissues excised from CT26-HER2/neu–TBM on day 23 after three treatments with HCT-mono-mIL12 (Figure 5A). This evidence concerns the gene CD8A and neoplasm.